Skip to main content

Advertisement

Table 2 Baseline characteristics

From: Agreement between cystatin-C and creatinine based eGFR estimates after a 12-month exercise intervention in patients with chronic kidney disease

Variable Control (n = 68) LI (n = 74) p value
Age (years) 63.5[9.4] 60.5[14.2] 0.23
Male sex, n(%) 41(60.3) 44(59.5) 0.92
African, n(%) 0(0) 1(1.4) 0.34
Diabetes, n(%) 27(42.2) 32(43.8) 0.85
Systolic blood pressure (mmHg) 133[26.5] 130[18] 0.18
Diastolic blood pressure (mmHg) 80[12] 78[10] 0.56
Medications
 ACE inhibitor, n(%) 34(53.1) 34(47.9) 0.54
 ARB, n(%) 30(45.5) 44(59.5) 0.10
 Thiazide, n(%) 16(25) 13(18.3) 0.35
 Spironolactone, n(%) 1(1.4) 3(4.9) 0.89
 Loop diuretics, n(%) 14(20.6) 15(21.2) 0.24
 Statin, n(%) 41(64.1) 46(64.8) 0.93
Primary cause of renal disease
 Glomerular nephritis, n(%) 2(2.9) 7(9.5) 0.11
 Analgesic nephropathy, n(%) 0(0) 2(2.7)  
 Renal vascular disease, n(%) 5(7.4) 5(6.8) 0.89
 Polycystic kidney disease, n(%) 4(5.9) 4(5.4) 0.90
 Reflux nephropathy, n(%) 1(1.5) 1(1.4) 0.95
 Pyelonenephritis, n(%) 1(1.5) 1(1.4) 0.95
 Calculi, n(%) 0(0) 1(1.4)  
 Type 1 diabetes (insulin), n(%) 0(0) 1(1.4)  
 Type 2 diabetes (non-insulin), n(%) 3(4.4) 5(6.8) 0.55
 Type 2 diabetes (insulin), n(%) 10(14.7) 5(6.8) 0.12
 Focal segmental glomerulosclerosis, n(%) 3(4.4) 2(2.7) 0.58
 IgA nephropathy, n(%) 4(5.9) 4(5.4) 0.90
 Other, n(%) 24(35.3) 21(28.4) 0.38
 Unknown, n(%) 5(7.4) 6(8.1) 0.87
  1. ACE angiotensin-converting-enzyme, ARB angiotensin receptor blocker. Median[IQR] and n(%) is reported